ArticleACS omega2025
Opioids in the Brazilian Healthcare Landscape: Crucial Analysis through Anvisa VigiMed Data and Pharmacogenetic Aspects.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse Drug Reactions (ADRs) present a significant challenge to healthcare systems, contributing substantially to hospital admissions. Opioid analgesics are widely used in the pharmacological treatment of various types of pain; however, ADRs represent a major limitation to their use. This study aims to investigate the profile of ADRs reported in Vigimed (the official Brazilian ADR reporting system) following the implementation of active surveillance through pharmacovigilance trackers. Additionally, it evaluates pharmacogenetic evidence to identify genes potentially involved in opioid-related ADRs. This retrospective cross-sectional study analyzed ADR cases reported to Vigimed from January 2018 to April 2023. Data were extracted from Vigimed, tabulated, and subjected to statistical analysis, using the reporting odds ratio (ROR) to assess the strength of associations between opioids and ADRs. During the study period, there were 238,363 ADR reports, of which 6,001 were related to opioid treatment. The distribution among opioids was as follows: 36.7% morphine, 32.4% tramadol, 21.6% fentanyl, 5.4% methadone, 3.7% codeine, and 0.2% oxycodone. The most frequent adverse events associated with opioids were cardiac disorders (ROR 1.70), skin and subcutaneous tissue disorders (ROR 2.18), gastrointestinal disorders (ROR 2.88), and nervous system disorders (ROR 1.19). Furthermore, pharmacogenetic evidence indicates that the
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.